Vimarsana
Biggest News Aggregation in the World

Page 4 - Recommended Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Recommended Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Recommended Phase Today - Breaking & Trending Today

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors - Vimarsana News

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer - Vimarsana News

Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones - Vimarsana News

Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML...

Oryzon Genomics S A : reports financial results and corporate updates for half-year ending June 30, 2023 - Vimarsana News

Oryzon Genomics S A : reports financial results and corporate updates for half-year ending June 30, 2023

24 July 2023 ORYZON reports financial results and corporate updates for half-year ending June 30, 2023 Positive aggregate safety data from...

ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023 - Vimarsana News

ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023

24.07.2023 - Positive aggregate safety data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the drug is safe and well-toleratedContinues to enroll ...